Skip to main content
Equibles
OCUL logo

OCUL · Ocular Therapeutix, Inc · Metrics

Track OCUL — free

Use OCUL with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research OCUL.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$10.62 -0.85 (-7.41%) At close · Sep 10
Russell 2000 member Rebalance outlook locked
Market Cap
$2.52B
Shares
219.62M

OCUL metrics

67 of 115 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$10.62
Market cap
$2.52B

Price action

20 metrics
Price change (1W)
+5.2%
Price change (30D)
+17.5%
Price change (3M)
+31.2%
Price change (6M)
+20.7%
Price change (YTD)
-5.5%
Price change (1Y)
-10.1%
Trailing year
Price change (5Y)
+2.0%
52-week high
$16.11
52-week low
$6.88
Change from 52-week high
-28.8%
Change from 52-week low
+66.7%
Annualized volatility
70.8%
Annualized volatility (3M)
51.6%
Beta
1.0
RSI (14D)
65.5
Price vs SMA 50
+16.8%
Price vs SMA 200
+15.4%
Avg volume (3M)
2.66M
Relative volume
1.1
Average dollar volume
$26.16M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
219.62M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
48.4×
reciprocal yield 2.1%
P / book
4.8
reciprocal yield 20.6%
FCF yield
-10.1%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-12.0%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-08-03

Profitability

9 metrics
Gross margin
87.1%
Operating margin
-603.0%
Trailing 12 months
Net margin
-579.1%
Gross profit (TTM)
—
Operating profit (TTM)
−$313.91M
Net income (TTM)
−$301.45M
Trailing 12 months
Diluted EPS (TTM)
$-1.40
FCF margin
-490.1%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$3.03

Growth

11 metrics
Revenue growth YoY
+0.1%
Year over year
Net income growth YoY
—
Revenue (TTM)
$52.05M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+30.3%
Year over year · more shares
Revenue CAGR (3Y)
+0.3%
Revenue CAGR (5Y)
+24.4%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-58.0%
Return on assets
-44.9%
Debt / equity
—
Current ratio
13.1
EBITDA (TTM)
−$308.46M
Free cash flow (TTM)
−$255.10M
Quick ratio
13.0
Interest coverage
-27.5
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$598.64M
Total assets
$671.32M
Total debt
$18.00M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$238.24M
Capital expenditures (TTM)
$16.86M
R&D (TTM)
$223.51M
SG&A (TTM)
—
Stock compensation (TTM)
$53.28M
R&D / revenue
429.4%
Stock compensation / revenue
102.4%

Ownership (13F)

3 metrics
13F filers
262
13F filer change QoQ
-13
Institutional ownership
94.3%

Short interest

3 metrics
Short interest
12.8%
Latest settlement · 9.0 days to cover
Days to cover
9.0d
Short-squeeze score
77 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$333,081
Insider-sentiment score
60 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 1393434 CUSIP 67576A100 13F (30d) 153 filings 150 filers Visit website Investor relations